Cerner working with Elligo, Frenome on multiomics for early cancer detection

Cerner this week announced that it’s taking part with Elligo Health Evaluate and Freenome for a clinical trial challenge that seeks to come early cancer detection by job of insights derived from Cerner’s Studying Health Network.


The three corporations will likely be harness valid-world data from the community’s taking part health scheme and utilize Freenome’s “multiomics” technology for the Sanderson Look for, an approaching near clinical trial designed to detect more than one forms of cancer.

Freenome’s platform uses machine finding out units to analyze tumor and non-tumor indicators, with the just of detecting cancer in its earliest, most treatable phases with a single blood plot. The just is to innovate a more patient-centric ability to multi-cancer detection, cutting back diagnostic complexity and optimizing processes for clinical effectivity.

Elligo Health Evaluate, will work with Studying Health Network participants to flee situation activation and sign up a trim volume of sufferers much quicker than dilapidated recruitment units, officers snarl, enabling various nationwide patient participation, spanning many demographics and communities.

“Sooner clinical reports suggest quicker run to market, meaning more sufferers getting the medication and technologies they want, sooner,” said Elligo CEO John Potthoff in an announcement. “Elligo’s platform, along with Cerner’s Studying Health Network, has the ability to noticeably run up startup and engagement with thousands of sufferers for any watch.”


Cerner first launched the Studying Health Network in collaboration with Duke Clinical Evaluate Institute in 2019, with the mission of helping lifestyles sciences, pharma and healthcare researchers rep more uncomplicated salvage admission to to aggregated clinical data. The challenge started that 12 months with a pilot centered on cardiovascular illness.

Cerner notes that this original initiative will likely be one of many principle cancer-screening trials available to the quick-rising LHN, which now contains some 85 health methods across the U.S. working collectively to expand salvage admission to to clinical trials by contributing de-known data.

The challenge is being driven by Cerner’s original Enviza industry unit, which used to be fashioned this previous October to elongate the provision of deidentified datasets and other valid-world evidence for learn on diagnostics and therapeutics.


“The clinical learn Cerner will enable has the doable to come early cancer detection so sufferers can concept timely treatment and enhance their prospects of survival,” said Christy Dueck, vp of Cerner Enviza, in an announcement. “Data and technology rep the ability to abet clinicians and researchers lengthen therapeutic data and run up their building and present, which is prepared to enhance of us’s lives spherical the enviornment.”

“Our long-term just is to come multi-cancer merchandise into clinical prepare to set apart more lives,” added Riley Ennis, Freenome’s chief product officer. “This collaboration with Cerner and Elligo will enable us to generate valid-world evidence and salvage our clinical reports available to more of us, to set apart more lives.”

Twitter: @MikeMiliardHITN

Email the creator: [email protected]

Healthcare IT Files is a HIMSS publication.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button